Clinical Trial Update: Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating efficacy and safety of a 2 mL auto-injector of secukinumab (300 mg) in moderate to severe plaque psoriasis has completed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Plaque Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2021-08-26